日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care

INFINITY精准肿瘤学注册研究的最终结果：常规护理中晚期癌症患者的非标准靶向治疗

期刊:
影响因子:
doi:10.1016/j.esmorw.2025.100667
Sellmann, L; Marschner, D; Martens, U M; Schröder, J; Decker, T; Schuler, M; Schneeweiss, A; Reiser, M; Schuler, M K; Vannier, C; Looß, M; Woerner, S M; Grebhardt, S; Wright, P R; Dille, S; Kasenda, B; Busies, S; Potthoff, K
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

INFINITY 研究方案：一项回顾性队列研究，旨在探讨生物标志物驱动的精准肿瘤学在常规临床实践中的决策制定和临床影响。

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-11046-3
Martens, Uwe M; Schröder, Jan; Bengsch, Fee; Sellmann, Ludger; Busies, Sabine; Frank-Gleich, Stefanie; Zaiss, Matthias; Decker, Thomas; Schneeweiss, Andreas; Schuler, Martin; Grebhardt, Sina; Zacharias, Stefan; Marschner, Norbert; Kasenda, Benjamin; Potthoff, Karin; Vannier, Corinne
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial

卡培他滨联合贝伐单抗，加或不加长春瑞滨一线治疗HER2/neu阴性转移性或局部晚期乳腺癌：随机、开放标签的3期优效性CARIN试验的最终疗效和安全性数据

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-016-3727-x
Welt, A; Marschner, N; Lerchenmueller, C; Decker, T; Steffens, C-C; Koehler, A; Depenbusch, R; Busies, S; Hegewisch-Becker, S
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2016
文献求助 收藏